Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects

Article ID	Journal	Published Year	Pages	File Type
5552202	Biochemical Pharmacology	2017	45 Pages	PDF

Keywords

mTOR FADD Bcl-xL BH3 mimetics IP3R ABT-737 ERK Bcl-2 Mcl-1 Bcl-2-like protein 11 BH3 interacting-domain death agonist bcl-w Jnk phorbol-12-myristate-13-acetate-induced protein 1 B-cell lymphoma extra-large BCL-2 related ovarian killer AMPK 5′AMP-activated protein kinase c-Jun N-terminal kinase p53 upregulated modulator of apoptosis Akt AIF Noxa Obatoclax Bax BAD BIK tumor necrosis factor α Bcl-2 family Bcl-2 homology domain RIPK endoplasmic reticulum apoptosis-inducing factor TNF-α Anticancer activity B-cell lymphoma 2 Myeloid cell leukemia 1 BIM Bcl-2-associated death promoter mammalian target of rapamycin Bcl-2-associated X protein Fas-associated protein with death domain protein kinase B receptor-interacting protein kinase BAK PUMA BID Bok Gossypol Inositol 1,4,5-trisphosphate receptor

Related Topics

Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology

Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects

Authors

MaÅgorzata Opydo-Chanek, Oscar Gonzalo, Isabel Marzo,